| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-02-29 | biocrea (Germany) Boehringer Ingelheim (Germany) | phosphodiesterase (PDE) platform including PDE2 inhibitors and BCA909 | undisclosed | licensing |
undisclosed | Licensing agreement |
| 2012-02-29 | Cobra Biologics (UK) undisclosed clinical stage biotechnology company | live bacteria | undisclosed rare genetic disease | production |
Genetic diseases - Rare diseases - Metabolic diseases | Production agreement |
| 2012-02-28 | Lundbeck (Denmark) Paion (Germany) Bayer (Germany) | desmoteplase | acute ischaemic stroke | acquisition |
Cerebrovascular diseases | Product acquisition |
| 2012-02-27 | Parsortix (UK) The Paterson Institute for Cancer Research (UK) | cancer biomarkers based on circulating tumour cells, optimization of Parsotix's device | cancer | R&D | Cancer Oncology | |
| 2012-02-27 | EMD Millipore, Life Science division of Merck KGaA - Germany (USA) Charles River Laboratories (USA) | TrueSpike™ technology | licensing |
Technology - Services | Licensing agreement | |
| 2012-02-27 | Angiochem (Canada) GSK (UK) | treatment for lysosomal storage diseases (EPiC (Engineered Peptide Compound)-enzymes) | lysosomal storage diseases | R&D |
Rare diseases - Genetic diseases - Metabolic diseases | Development agreement |
| 2012-02-22 | Apceth (Germany) Indivumed (Germany) | biomarker platform for targeted cellular therapies | cancer | development |
Cancer - Oncology | Development agreement |
| 2012-02-22 | Roche (Switzerland) Life Technologies Corporation (USA) | PCR-related technologies for in vitro diagnostics applications | licensing |
Licensing agreement | ||
| 2012-02-22 | Oxford Gene Technology (UK) Inven2 (Norway) University of Oslo (Norway) | colorectal cancer tissue biomarkers | colorectal cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2012-02-21 | Boehringer Ingelheim (Germany) Xencor (USA) | biosuperior monoclonal antibodies | undisclosed | development |
undisclosed | Production agreement |
| 2012-02-20 | Dako (Denmark) Amgen (USA) | diagnostic test for an Amgen cancer drug candidate in clinical development | undisclosed cancer | development |
Cancer - Oncology | Development agreement |
| 2012-02-20 | Lanthio Pharma (The Netherlands) Tarix Pharmaceuticals (USA) | lanthionine-stabilized Angiotensin agonistic peptide drug | acute lung injury and related indications with high unmet medical need | licensing |
Lung diseases | Licensing agreement |
| 2012-02-17 | Abcodia (UK) VolitionRX (Singapore) | biomarkers for the early detection of cancer (nucleosome-based diagnostic tests for lung, colorectal and pancreatic cancer) | lung cancer, colorectal cancer, pancreatic cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2012-02-16 | Evotec (Germany) IR Pharma (UK) | integrated drug discovery solutions | R&D |
Respiratory diseases | R&D agreement | |
| 2012-02-16 | Critical Pharmaceuticals (UK) The University of Nottingham (UK) | nano-enabled intranasal formulation of teriparatide | osteoporosis | R&D |
Bone diseases | R&D agreement |
| 2012-02-14 | Pharming (The Netherlands) Transmedic Pte (Singapore) | Ruconest® (Rhucin® in non-European territories - conestat alfa) | acute angioedema attacks in patients with Hereditary Angioedema (HAE) | commercialisation |
Rare diseases - Genetic diseases | Commercialisation agreement |
| 2012-02-10 | UCB (Belgium) Nodality (USA) | Single Cell Network Profiling (SCNP) technology - companion diagnostics | immunology disorders | R&D |
Immunological diseases | R&D agreement |
| 2012-02-09 | Bayer (Germany) - Almirall (Spain) | Xarelto® (rivaroxaban) | prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors, treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults, and prevention of VTE in adult patients undergoing elective hip or knee replacement surgery. |
co-promotion |
Cardiovascular diseases - Cerebrovascular diseases | Co-promotion agreement |
| 2012-02-07 | Sanofi (France) Rib-X Pharmaceuticals (USA) | new antibiotics for treatment of MDR pathogens (RX-04 program) | R&D |
Infectious diseases | Milestone | |
| 2012-02-07 | Siemens Healthcare Diagnostics (USA), subsidiary of Siemens AG (Germany) ViiV Healthcare (USA) | companion diagnostic for Celsentri/Selzentry® (maraviroc) | HIV-Aids | R&D, development, commercialisation | Infectious diseases | Development agreement |
